ENG/中
老虎证券
行情
交易
收费
下载
优惠与活动
帮助
TigerAI
机构
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
股权激励
关于
登录
立即注册
Toggle
美股
详情
本页面由Tiger Trade Technology Pte. Ltd.提供服务
Valero Energy Partners LP
42.24
0.0000
成交量:
- -
成交额:
- -
市值:
29.26亿
市盈率:
14.85
高:
42.24
开:
42.24
低:
42.24
收:
42.24
52周最高:
48.66
52周最低:
33.25
股本:
6,926.21万
流通股本:
1,663.00万
量比:
- -
换手率:
- -
股息:
- -
股息率:
- -
每股收益(TTM):
2.84
每股收益(LYR):
2.78
净资产收益率:
--
总资产收益率:
--
市净率:
10.31
市盈率(LYR):
15.22
数据加载中...
总览
公司
新闻资讯
公告
这个千亿赛道,正悄然爆发新机会
丁香园 Insight 数据库
·
2025/11/05
Biogen终止AAV基因治疗业务!AAV已成时代眼泪?
谈思生物
·
2025/09/29
{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券 | 轻松买卖美股港股A股/美债/ETF/Crypto/期权期货","description":"老虎证券提供多项优惠: 港股&Crypto 0佣0平台费、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投,免费实时行情与多种工具,立即开户享更多优惠!","keywords":"老虎证券,老虎证券开户,老虎证券香港,老虎证券登录,老虎证券官网,香港证券开户,证券公司开户,股票开户,香港证券公司,香港证券,证券公司,股票投资,投资app,投资平台,股票买卖,股票交易平台,股票app,证券app,新手投资","social":{"ogDescription":"老虎证券提供多项优惠: 港股&Crypto 0佣0平台费、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投,免费实时行情与多种工具,立即开户享更多优惠!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/VLP/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"VLP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VLP\",,,,,undefined,":{"symbol":"VLP","market":"US","secType":"STK","nameCN":"Valero Energy Partners LP","latestPrice":42.24,"timestamp":1575925200000,"preClose":42.24,"halted":4,"volume":0,"delay":0,"changeRate":0,"floatShares":16630000,"shares":69262070,"eps":2.843937,"marketStatus":"退市","change":0,"latestTime":"12-09 16:00:00 EST","open":42.24,"high":42.24,"low":42.24,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.843937,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1771837200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1386738000000,"exchange":"NYSE","adjPreClose":42.24,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VLP\",,,,,undefined,":{"symbol":"VLP","floatShares":16630000,"roa":"--","roe":"--","lyrEps":2.775139,"shares":69262070,"dividePrice":0,"high":42.24,"amplitude":0,"preClose":42.24,"low":42.24,"week52Low":33.25,"pbRate":"10.31","week52High":48.66,"institutionHeld":0,"latestPrice":42.24,"eps":2.843937,"divideRate":0,"volume":0,"delay":0,"ttmEps":2.843937,"open":42.24},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/VLP\",params:#limit:5,,,undefined,":[{"market":"US","date":"2018-10-31","symbol":"VLP","amount":0.551,"name":"Valero Energy Partners LP","currency":"USD","type":"dividend","dateTimestamp":1540958400000},{"market":"US","date":"2018-10-25","symbol":"VLP","fiscalQuarterEnding":"2018/09","expectedEps":0.68,"name":null,"time":"盘前","type":"earning","dateTimestamp":1540440000000,"reportTimeType":"pre","actualEps":0.75},{"market":"US","date":"2018-08-02","symbol":"VLP","amount":0.551,"name":"Valero Energy Partners LP","currency":"USD","type":"dividend","dateTimestamp":1533182400000},{"market":"US","date":"2018-07-26","symbol":"VLP","fiscalQuarterEnding":"2018/06","expectedEps":0.66,"name":null,"time":"盘前","type":"earning","dateTimestamp":1532577600000,"reportTimeType":"pre","actualEps":0.66},{"market":"US","date":"2018-04-30","symbol":"VLP","amount":0.5275,"name":"Valero Energy Partners LP","currency":"USD","type":"dividend","dateTimestamp":1525060800000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"VLP\",market:\"US\",,,undefined,":[{"executeDate":"2017-01-31","recordDate":null,"paymentDate":null,"value":0.4065,"currency":"USD"},{"executeDate":"2017-04-28","recordDate":null,"paymentDate":null,"value":0.4275,"currency":"USD"},{"executeDate":"2017-07-28","recordDate":null,"paymentDate":null,"value":0.455,"currency":"USD"},{"executeDate":"2017-10-31","recordDate":null,"paymentDate":null,"value":0.48,"currency":"USD"},{"executeDate":"2018-02-02","recordDate":null,"paymentDate":null,"value":0.5075,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"VLP\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"VLP\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2581840799","title":"这个千亿赛道,正悄然爆发新机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2581840799","media":"丁香园 Insight 数据库","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581840799?lang=zh_cn&edition=fundamental","pubTime":"2025-11-05 07:50","pubTimestamp":1762300219,"startTime":"0","endTime":"0","summary":"一方面,全球已获批上市及在研的 CAR-T 疗法靶点过度集中在 CD19 和 BCMA,且适应症主要为血液恶性肿瘤,市场竞争十分激烈。另一方面,价格高昂是 CAR-T 疗法的鲜明标识。例如,瑞基奥仑赛注射液的销售额一路下滑,2023 年上半年、2024 上半年、2025 年上半年分别为 8774 万元、8680 万元、8100 万元。MNC 集体逃离背后CGT 赛道的光鲜背后,实则暗藏隐忧。是什么让这个曾经备受追捧的赛道,在短短数年间迅速滑落?其三,布局体内 CAR-T 疗法,显著简化流程并降低成本。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251105075250a488e8f5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251105075250a488e8f5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GILD","02196","BK4022","BK4230","IE00BKVL7J92.USD","VLP","LU0154236417.USD","02126","PFE","IE00BZ1G4Q59.USD","CAR","BMS","LU1093756325.SGD","BK4599","LU1093756168.USD","BK4007","BK4585","BK4588","BK4532","NVO"],"gpt_icon":1},{"id":"2571129387","title":"Biogen终止AAV基因治疗业务!AAV已成时代眼泪?","url":"https://stock-news.laohu8.com/highlight/detail?id=2571129387","media":"谈思生物","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571129387?lang=zh_cn&edition=fundamental","pubTime":"2025-09-29 15:37","pubTimestamp":1759131457,"startTime":"0","endTime":"0","summary":"近期,全球中枢神经赛道的霸主渤健一纸声明,彻底砍掉所有依托腺相关病毒外壳的基因疗法管线。当基因治疗赛道由“高烧”转入“退烧”周期,跨国巨头们接连给AAV踩下急刹。2023年,武田率先把AAV基因疗法与血液罕见病的早期项目全部封存;转眼新年,辉瑞干脆把才上市满周岁的Beqvez撤出市场,十年押注一朝清零。近年,辉瑞、CRISPR Therapeutics的临床项目相继曝出受试者死亡;2025年,Sarepta的Elevidys再添三例疑似治疗相关命案,直接触发停售,把AAV推到舆论火山口。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250929154002a44bc115&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250929154002a44bc115&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1861558580.USD","CNS","BK4135","LU1861559042.SGD","PFE","BK4585","BK4588","BK4556","BK4611","CRSP","VLP","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":2,"code":"91000000","status":"200"}]}}